https://www.selleckchem.com/pr....oducts/4-hydroxytamo
r postmortem validation, and a lack of generalizability to nonprofessional athletes. CONCLUSIONS The most promising biomarker is tau-binding radionuclide PET signal because it is most specific to the underlying neuropathology and differentiated CTE from both controls and patients with Alzheimer disease (P less then 0.0001). Multimodal imaging will improve specificity further. Future research should minimize variability in identification of suspected cases of CTE using published clinical criteria.A 46-year-old
Aimer
Commentaire
Partagez
